The global Tralokinumab market size was valued at USD 500.50 million in 2024 and is expected to reach USD 1,275.07 million by 2032, at a CAGR of 12.40% during the forecast period

The market growth is largely fueled by the growing prevalence of inflammatory skin conditions and increased adoption of targeted biologic therapies such as Tralokinumab, which is a humanised monoclonal antibody targeting IL‑13

Furthermore, rising demand for effective, safe and well‑tolerated biologic treatments in dermatology and the expansion of reimbursement and awareness in key markets are establishing Tralokinumab as a modern therapy choice. These converging factors are accelerating the uptake of Tralokinumab, thereby significantly boosting the industry’s growth